Boehringer Ingelheim acquires equine health startup Evax
News 14.08.2026 Boehringer Ingelheim has acquired Evax AG, a Swiss biotech company focused on therapeutic vaccines to address significant unmet needs in horses, particularly for the treatment of allergic skin diseases. Allergies and dermatologic conditions in horses are common and have a significant impact on their health and well-being yet are very challenging to treat....